Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Agree DR, I would as well. I think GM would want to close off his era as positively as he can.
I also wonder how much of the £4.7m contract under the new framework has been spent already, presumably with a 34% increase in PCR testing in Q3 (source below) compared to Q2, then it will be challenging for it to last to March 2022. How much of that income will we receive this year and will there be a new contract if they go through the £4.7m?
https://coronavirus.data.gov.uk/
Agree, even if it is £30m for Q3 then we’ll have £84m, with £16m to deliver in Q4 to achieve £100m FY forecast. So anything higher than £30m then we should have a revision as it’ll be material (ie +10% above forecast). Am hoping we’ll get it on or before 18/10. DA may want a little more time before giving a really bullish early message, but suspect he’s reviewing it all behind the scenes (as most high level appointments do, in my experience), if not Graham might want to end on a high with getting some good messages out at the end…
@Wilson I’d also hope for a Q3 update, especially if H2 is going to be materially different (positive or negative) to the £46m forecast, to deliver £100m FY ex.DHSC. I’ve pulled out the 2021 and 2021 H1 Results Outlooks below. The 2021 Outlook is pretty scant compared to 2020! Are they holding something back to release on 18/10 or before?
2021 H1 Results
“Outlook
The Company reiterates full year 2021 revenue and EBITDA guidance announced on 16 September 2021.”
https://www.lse.co.uk/rns/NCYT/half-year-2021-results-25htu0dw34gr5u4.html
2020 H1 Results
“Outlook
Novacyt's near-term focus is to deliver strong organic revenue growth in the core business, where the Directors believe demand for its products will continue to grow into at least H1 2021 as COVID-19 testing continues. In the medium-term, Novacyt expects to leverage its reputation, market intelligence and relationships developed during the COVID-19 response to commercialise new products, as well as expand its presence in respiratory and transplant clinical diagnostics, to meet significant unmet market needs. The Directors expect to supplement the Company's product portfolio and expand its core capabilities through executing selective and accretive M&A at the right time.
The Directors reiterate guidance announced on 13 July 2020; given the visibility of orders, extended contracts and the launch of new COVID-19 related products, revenue for the second half of the year is expected to be greater than the first half of the year and margins to be at least at a similar level. Full year revenues are expected to exceed €150 million and EBITDA profitability to exceed €100 million. The Company expects this rate of financial performance to extend into the first half of 2021. The Directors remain confident in and excited by the prospects of the business, not only for the short-term, but also for the longer-term.”
https://www.lse.co.uk/rns/NCYT/half-year-2020-results-dvhjx43wa68ku5w.html
I agree PI100 “you (as we all can) only judge by what you see/read.”
There should be a healthy dose of cynicism for motives of all posters (me included). Rampers as well as Derampers. Everyone should DYOR and make up their own minds and remember that you can view a posters history and make up your own mind if they have an agenda or not.
I look at @jaspertown asking you for a view on what’s going to happen this morning, but then I remember your comment “albeit I am an inexperienced investor who is still learning. “ from “RE: Yesterday rise 22 Sep 2021 10:27” and I think why would they ask you. I also look back at another post
“RE: LATEST CHART
01 Oct 2021 17:31
Is this the rampers thread? OP appears to be one and good old porky has popped up. Please, novices, don’t listen to a word they say.”
Where you don’t seem to be so inexperienced…
You’ve also gone very quiet on EZJ where your posts had a similar tone, but since the rights issue went swimmingly well (I’m a LTH there), you’ve gone mysteriously quiet…
I think that everyone should read everything, but rely on your research when making any decisions.
I agree, though with the BOD holding such little volume of shares they should at least inform us of any approaches. I did ask as one of my Qs for the Investor Presentation whether they had had any approaches (which they didn’t answer, will ask again for AGM) they should inform SHs, plus it wouldn’t hurt the SP to know that there is interest out there, even if offer is too low to entertain
Let’s not get carried away. The SP is not flying. If there was any sniff of a T/O then in my IMO it would fly up a lot quicker.
It would just be nice to have a run of the SP going up steadily each day, ahead of some good news to then get it back closer to where it should actually be
Nova’s SP just seems to rise and fall without any explanation
Thanks to Baan
https://twitter.com/baan36015541/status/1444270513665290251?s=21
6th highest since start of the pandemic. My kids’ school had an outbreak on Friday, which I suspect is being replicated up and down the country.
Poidster - any view on when the £4.7m worth of Promate under the new framework will run out? Surely it can’t last until March 2022, based on these volumes…
Kitzie, if you click on the vote login link then your original votes will be shown, you can change what you voted for now though if you want to
JCB, just take a screenshot of your holding and upload it on the voting link. That will be accepted
I don’t think it will change demand in the short/medium term as the treatments will be expensive and most effective for those that have Covid, and they will need to be tested to confirm that.
I’ve lost the plot with sentiment on NCYT, feels like any piece of news has a negative impact. We’re at the highest tests per day in the UK (473,769) since 09/01 and that still doesn’t seem to change anything…
Merck article
“One challenge will be making sure the drug is available when people need it, and one challenge could be price. In June, Merck entered into an agreement to supply the U.S. government 1.7 million courses of the drug for $1.2 billion, or $700 a course. That price could be out of reach for some countries. But Merck also has said it will enter into licensing agreements with generic drug makers to accelerate the availability of the drug in more than 100 low- and middle-income countries. “We are committed to making sure that there is access to this drug,” Daria Hazuda, a Merck vice president, told reporters on a conference call Friday morning.”
https://www.statnews.com/2021/10/01/mercks-antiviral-pill-reduces-hospitalization-of-covid-patients-a-possible-game-changer-for-treatment/
Gazman, wondering if it’s delayed because they’re struggling to count all of the tests conducted! ;)
“An extra £388 million has been earmarked by ministers to prevent coronavirus and flu infections and provide testing in the care sector this winter.
The new funding, announced last night by Sajid Javid, the health and social care secretary, includes £25 million to support care workers to access vaccination, including covering the costs of travelling to appointments.”
“The funding will also include £237 million for infection control and £126.3 million for the testing of staff, residents and others to enable visits.”
https://apple.news/ANvsLHnyCRVaYBi1TDHJjVg
And we have a solution for this need
https://testandyou.org/sector/care-homes
And presumably “next month” is now and so it’s launched!
I don’t know either Gazman why IIs aren’t investing, some people will say lack of certainty due to DHSC, but that’s now priced in/written off, with an additional contract bagged, others might say what about post-Covid revenue, but with significant cash at the bank, great innovations, and a global distribution network I think that there is a strong future post Covid in a massive global diagnostics market. Others might say well they don’t want to invest in cash (ie our CAB being almost half the MCAP), as they want their cash to make a return - we really can’t win here, other investors will take punts at companies that have little or no revenue and whom might deliver at some point in the future. We’ve got strength and resilience with significant CAB and are delivering significant revenue! I think it comes down to sentiment and engagement with investors. Having watched the You Tube video of DA in action I’ve got confidence, IMO, that it is going to markedly improve in the future.
I wondered that Saintsmith. I can understand co-developed with divisions within Novacyt, but why do we need to develop with anyone outside of the company? We’ve got all we need with IT-IS and Primerdesign for this, haven’t we?!?
Clearly a mixed RNS, but we delivered £10m per month revenue in June and £54m H1, without the new LFT revenue. £100m FY 21 should still be achievable and the LFT revenue would have been on top of that. Though am wondering whether if we’re facing these issues are the other LFT manufacturers in the same boat? Feel nuts as the U.K. can’t switch from PCR for travel due to lack of capacity, can’t believe it takes 6 months to approve! Official announcement on Co-Prep is exciting though for now and the future!
Didn’t say that they’d answer any of them :)
wonder if they might take electronic questions and then decide which ones they want to answer. Though saying all of that there is no questions slot on the Agenda. I wonder if Open means that they won’t restrict attendance just to those that have gone on to the website, proved they have a share holding and have signed the vote submission. Though that won’t encourage those that haven’t already voted to actually vote.
Don’t know the difference. May be we can ask live questions in an open meeting, but am just guessing.
I saw that 1% figure being banded about, but is there any actual evidence of it? Institutions own 4.2% and BoD own 0.4% and I would have expected all of them to have voted, either for or against.